Polyrizon Ltd. reported that its Trap & Target (T&T) intranasal naloxone hydrogel achieved markedly higher mucoadhesion than the currently marketed intranasal naloxone spray in an ex‑vivo rabbit nasal mucosa study. The hydrogel retained significantly more residual fluorescence after 30 minutes of washing with simulated nasal electrolyte solution, with a p‑value of less than 0.0001, indicating a robust statistical difference.
The enhanced mucoadhesion suggests the hydrogel could maintain therapeutic drug levels at the nasal mucosa for a longer period, potentially improving absorption and onset of action for opioid‑overdose reversal. Polyrizon’s CEO, Tomer Izraeli, said the results “validate the potential of our T&T hydrogel platform and highlight its unique advantages in intranasal drug delivery.” The company’s strategy is to develop a more reliable, non‑invasive naloxone delivery system that could differentiate it from existing products in a crowded market.
Polyrizon is a development‑stage biotech with a strong cash position but negative earnings and a high cash burn. The preclinical milestone is a key step toward commercializing its naloxone program and supports the company’s broader pipeline, which includes Capture and Contain (C&C) technologies for viral and allergen barriers. The intranasal naloxone market is growing, driven by the need for rapid, user‑friendly overdose reversal, and Polyron’s technology could offer a competitive edge by extending the drug’s residence time in the nasal cavity.
While the announcement does not affect current financial results, it signals progress toward a potential future product launch and may influence investor expectations about Polyrizon’s pipeline valuation. The company’s recent share price movements—an 80% surge after a manufacturing upscaling announcement on December 2—reflect heightened investor interest in its development milestones.
Polyrizon’s next steps include scaling up preclinical studies, initiating IND‑enabling toxicology, and preparing for a Phase I clinical trial. The company’s management remains focused on advancing the T&T platform while maintaining disciplined cash management to support ongoing R&D and regulatory milestones.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.